Bassetti M.; Vena A.; Bouza E.; Peghin M.; Munoz P.; Righi E.; Pea F.; Lackner M.; Lass-Florl C., Antifungal susceptibility testing in Candida, Aspergillus and Cryptococcus infections: are the MICs useful for clinicians?, «CLINICAL MICROBIOLOGY AND INFECTION», 2020, 26, pp. 1024 - 1033 [articolo]
Abdul-Aziz M.H.; Alffenaar J.-W.C.; Bassetti M.; Bracht H.; Dimopoulos G.; Marriott D.; Neely M.N.; Paiva J.-A.; Pea F.; Sjovall F.; Timsit J.F.; Udy A.A.; Wicha S.G.; Zeitlinger M.; De Waele J.J.; Roberts J.A., Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#, «INTENSIVE CARE MEDICINE», 2020, 46, pp. 1127 - 1153 [articolo]
Cattani G.; Madia A.; Arnoldo L.; Brunelli L.; Celotto D.; Grillone L.; Valent F.; Castriotta L.; Pea F.; Bassetti M.; Brusaferro S., Assessment of the impact of clinical recommendations on antibiotic use for CAP and HCAP: results from an implementation program in an Academic Hospital, «ANNALI DI IGIENE MEDICINA PREVENTIVA E DI COMUNITÀ», 2020, 32, pp. 344 - 356 [articolo]
Cojutti P.G.; Londero A.; Della Siega P.; Givone F.; Fabris M.; Biasizzo J.; Tascini C.; Pea F., Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6, «CLINICAL PHARMACOKINETICS», 2020, 59, pp. 1251 - 1260 [articolo]Open Access
Giacobbe, Daniele Roberto; Ciacco, Eugenio; Girmenia, Corrado; Pea, Federico; Rossolini, Gian Maria; Sotgiu, Giovanni; Tascini, Carlo; Tumbarello, Mario; Viale, Pierluigi; Bassetti, Matteo, Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data, «INFECTION AND DRUG RESISTANCE», 2020, Volume 13, pp. 4697 - 4711 [articolo]Open Access
Pea F., From bench to bedside: Perspectives on the utility of pharmacokinetics/pharmacodynamics in predicting the efficacy of antifungals in invasive candidiasis, «MYCOSES», 2020, 63, pp. 854 - 858 [articolo]
Cojutti P.G.; Candoni A.; Lazzarotto D.; Fili C.; Zannier M.; Fanin R.; Pea F., Population pharmacokinetics of continuous-infusion meropenem in febrile neutropenic patients with hematologic malignancies: Dosing strategies for optimizing empirical treatment against enterobacterales and p. aeruginosa, «PHARMACEUTICS», 2020, 12, Article number: 785, pp. 1 - 11 [articolo]Open Access
Cojutti P.G.; Lazzarotto D.; Candoni A.; Dubbini M.V.; Zannier M.E.; Fanin R.; Pea F., Real-Time TDM-based optimization of continuous-infusion meropenem for improving treatment outcome of febrile neutropenia in oncohaematological patients: Results from a prospective, monocentric, interventional study, «JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY», 2020, 75, pp. 3029 - 3037 [articolo]Open Access
Cojutti, P.G.; Carnelutti, A.; Mattelig, S.; Sartor, A.; Pea, F., Real-Time Therapeutic Drug Monitoring-Based Pharmacokinetic/Pharmacodynamic Optimization of Complex Antimicrobial Therapy in a Critically Ill Morbidly Obese Patient. Grand Round/A Case Study, «THERAPEUTIC DRUG MONITORING», 2020, 42, pp. 349 - 352 [articolo]
Brancaccio, Gabriella; Pea, Federico; Moscarella, Elvira; Argenziano, Giuseppe, Sonidegib for the Treatment of Advanced Basal Cell Carcinoma, «FRONTIERS IN ONCOLOGY», 2020, 582866, pp. 1 - 7 [articolo]Open Access
Pea F., Teicoplanin and therapeutic drug monitoring: An update for optimal use in different patient populations, «JOURNAL OF INFECTION AND CHEMOTHERAPY», 2020, 26, pp. 900 - 907 [articolo]
Soriano A.; Rossolini G.M.; Pea F., The role of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs), «EXPERT REVIEW OF ANTI-INFECTIVE THERAPY», 2020, 18, pp. 415 - 422 [articolo]Open Access
Vena A.; Munoz P.; Mateos M.; Guinea J.; Galar A.; Pea F.; Alvarez-Uria A.; Escribano P.; Bouza E., Therapeutic Drug Monitoring of Antifungal Drugs: Another Tool to Improve Patient Outcome?, «INFECTIOUS DISEASES AND THERAPY», 2020, 9, pp. 137 - 149 [articolo]Open Access
Guaraldi G.; Milic J.; Cozzi-Lepri A.; Pea F.; Mussini C., Tocilizumab in COVID-19: finding the optimal route and dose – Authors' reply, «THE LANCET. RHEUMATOLOGY», 2020, 2, pp. E739 - E740 [replica/breve intervento]
Guaraldi G.; Meschiari M.; Cozzi-Lepri A.; Milic J.; Tonelli R.; Menozzi M.; Franceschini E.; Cuomo G.; Orlando G.; Borghi V.; Santoro A.; Di Gaetano M.; Puzzolante C.; Carli F.; Bedini A.; Corradi L.; Fantini R.; Castaniere I.; Tabbi L.; Girardis M.; Tedeschi S.; Giannella M.; Bartoletti M.; Pascale R.; Dolci G.; Brugioni L.; Pietrangelo A.; Cossarizza A.; Pea F.; Clini E.; Salvarani C.; Massari M.; Viale P.L.; Mussini C., Tocilizumab in patients with severe COVID-19: a retrospective cohort study, «THE LANCET. RHEUMATOLOGY», 2020, 2, pp. e474 - e484 [articolo]
